Votrient (pazopanib; Novartis) is an oral angiogenesis inhibitor targeting the vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), and c-KIT. Preclinical studies have shown the role of PDGF in modulating angiogenesis, and have demonstrated that inhibition of both PDGF and VEGF results in reduced tumor vascularization and greater growth inhibition.
Votrient (pazopanib; Novartis) is expected to struggle to retain market share as newer, more efficacious combinations enter the market. Votrient is not currently in development in combination with an immuno-oncology therapy, though Votrient + Keytruda (pembrolizumab; Merck & Co) was investigated in a Phase I/II clinical trial for the first-line treatment of advanced renal cell carcinoma (RCC) (ClinicalTrials.gov identifier: NCT02014636). In this trial, the combination showed significant hepatotoxicity, and was deemed not to be suitable to advance to Phase III trials. Further opportunity for Votrient in RCC may come following the result of an ongoing clinical trial investigating the efficacy and safety of Votrient in the second-line setting following treatment with a checkpoint inhibitor (ClinicalTrials.gov identifier: NCT03200717). As checkpoint inhibitors become increasingly important in the first-line treatment of advanced RCC, Votrient may be able to satisfy an unmet need and increase its market share
LIST OF FIGURES
13 Figure 1: Votrient for RCC – SWOT analysis
14 Figure 2: Datamonitor Healthcare’s drug assessment summary of Votrient for RCC
15 Figure 3: Datamonitor Healthcare’s drug assessment summary of Votrient for RCC
17 Figure 4: Votrient sales for RCC across the US, Japan, and five major EU markets, by country, 2017–26
LIST OF TABLES
5 Table 1: Votrient drug profile
7 Table 2: Votrient pivotal trial data in RCC
9 Table 3: Votrient Phase III data in RCC
12 Table 4: Votrient ongoing trials in RCC
18 Table 5: Votrient sales for RCC across the US, Japan, and five major EU markets, by country ($m), 2017–26
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.